Sign Out
Early breast cancer (EBC): Phesgo is indicated for use in combination with chemotherapy in: the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence (see Pharmacology: Pharmacodynamics under Actions); the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence (see Pharmacology: Pharmacodynamics under Actions).
Metastatic breast cancer (MBC): Phesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
